Download PDF
Semin Thromb Hemost 2013; 39(05): 507-514
DOI: 10.1055/s-0033-1343891
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cancer and Venous Thrombosis: Current Comprehensions and Future Perspectives

Mandy N. Lauw
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Frederiek F. van Doormaal
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Saskia Middeldorp
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Harry R. Buller
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
29 April 2013 (online)

    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a common complication in all types of cancer and adversely impacts cancer prognosis. Randomized controlled trials with primary thromboprophylaxis in cancer patients generally show effective VTE relative risk reductions of up to 60%. However, absolute risks of VTE were fairly low. Thromboprophylaxis should therefore only be recommended to cancer patients at highest risk of VTE, who may benefit most from prophylaxis. Predictive risk models to identify patients at a high risk of VTE are promising, however additional validation is required. An increasing proportion of cancer-associated VTE is formed by incidental VTE, with similar risk factors and clinical consequences. Randomized trials are not yet available, but it seems reasonable to treat incidental VTE similarly to symptomatic VTE. In a substantial proportion of patients with unprovoked VTE without known cancer at the time of VTE diagnosis, concomitant or occult cancer is identified. Studies have investigated the value of extensive screening over routine examinations alone for occult cancer. Although extensive screening may be able to identify more occult cancers, its clinical benefit over routine screening has not been demonstrated.

Keywords

cancer - incidental thrombosis - risk assessment - thromboprophylaxis - venous thromboembolism
 

  • References

  • 1 Bouillaud S. De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823; 1: 188-204
    PubMedGoogle Scholar
  • 2 Trousseau A. Phlegmasia alba dolens. In: Trousseau ed. Clinique medicinale de l'Hotel-Dieu de Paris. Paris: Bailliere J.-B. et fils; 1865: 645-712
    Google Scholar
  • 3 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6 (6) 401-410
    CrossrefPubMedGoogle Scholar
  • 4 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62 (1) 14-31
    PubMedGoogle Scholar
  • 5 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (4) 458-464
    CrossrefPubMedGoogle Scholar
  • 6 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (3) 632-634
    CrossrefPubMedGoogle Scholar
  • 7 Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160 (6) 761-768
    CrossrefPubMedGoogle Scholar
  • 8 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
    CrossrefPubMedGoogle Scholar
  • 9 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (6) 715-722
    CrossrefPubMedGoogle Scholar
  • 10 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9 (7) e1001275
    CrossrefPubMedGoogle Scholar
  • 11 Mandala M, Clerici M, Corradino I , et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol 2012; 23 (6) 1416-1421
    CrossrefPubMedGoogle Scholar
  • 12 Vemulapalli S, Chintala L, Tsimberidou AM , et al. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 2009; 84 (7) 408-413
    CrossrefPubMedGoogle Scholar
  • 13 White RH, Chew HK, Zhou H , et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165 (15) 1782-1787
    CrossrefPubMedGoogle Scholar
  • 14 Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27 (29) 4848-4857
    CrossrefPubMedGoogle Scholar
  • 15 Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Contr 2005; 12 (Suppl. 01) 5-10
    PubMedGoogle Scholar
  • 16 Lauw MN, Van der Holt B, Middeldorp S, Meijers JC, Cornelissen J, Biemond BJ. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. Thromb Haemost 2013; 109 (4) 109
    PubMedGoogle Scholar
  • 17 Mitchell L, Lambers M, Flege S , et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115 (24) 4999-5004
    CrossrefPubMedGoogle Scholar
  • 18 Otten HM, Mathijssen J, ten Cate H , et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164 (2) 190-194
    CrossrefPubMedGoogle Scholar
  • 19 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118 (5) 555-568
    CrossrefPubMedGoogle Scholar
  • 20 Palumbo A, Rajkumar SV, Dimopoulos MA , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (2) 414-423
    CrossrefPubMedGoogle Scholar
  • 21 Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160 (6) 761-768
    CrossrefPubMedGoogle Scholar
  • 22 Prandoni P, Lensing AW, Piccioli A , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 23 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6 (6) 401-410
    CrossrefPubMedGoogle Scholar
  • 24 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 25 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A , et al; RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (Suppl. 02) S58-S61
    CrossrefPubMedGoogle Scholar
  • 26 Mandalà M, Falanga A, Roila F. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
    CrossrefPubMedGoogle Scholar
  • 27 Kahn SR, Lim W, Dunn AS , et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S
    CrossrefPubMedGoogle Scholar
  • 28 Lyman GH, Khorana AA, Falanga A , et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25 (34) 5490-5505
    CrossrefPubMedGoogle Scholar
  • 29 Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119 (3) 648-655
    CrossrefPubMedGoogle Scholar
  • 30 Larocca A, Cavallo F, Bringhen S , et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119 (4) 933-939 , quiz 1093
    CrossrefPubMedGoogle Scholar
  • 31 Palumbo A, Cavo M, Bringhen S , et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29 (8) 986-993
    CrossrefPubMedGoogle Scholar
  • 32 Levine M, Hirsh J, Gent M , et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343 (8902) 886-889
    CrossrefPubMedGoogle Scholar
  • 33 Maraveyas A, Waters J, Roy R , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48 (9) 1283-1292
    CrossrefPubMedGoogle Scholar
  • 34 Perry JR, Julian JA, Laperriere NJ , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8 (9) 1959-1965
    CrossrefPubMedGoogle Scholar
  • 35 Agnelli G, Gussoni G, Bianchini C , et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
    CrossrefPubMedGoogle Scholar
  • 36 Agnelli G, George DJ, Kakkar AK , et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (7) 601-609
    CrossrefPubMedGoogle Scholar
  • 37 Haas SK, Freund M, Heigener D , et al; TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012; 18 (2) 159-165
    CrossrefPubMedGoogle Scholar
  • 38 Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2012; 2: CD008500
    PubMedGoogle Scholar
  • 39 Sideras K, Schaefer PL, Okuno SH , et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81 (6) 758-767
    CrossrefPubMedGoogle Scholar
  • 40 Altinbas M, Coskun HS, Er O , et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2 (8) 1266-1271
    CrossrefPubMedGoogle Scholar
  • 41 Kakkar AK, Levine MN, Kadziola Z , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22 (10) 1944-1948
    CrossrefPubMedGoogle Scholar
  • 42 Mitchell L, Andrew M, Hanna K , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90 (2) 235-244
    PubMedGoogle Scholar
  • 43 Riess H, Pelzer U, Hilbig A , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008; 8: 361
    CrossrefPubMedGoogle Scholar
  • 44 Levine MN, Gu C, Liebman HA , et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10 (5) 807-814
    CrossrefPubMedGoogle Scholar
  • 45 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 46 Ay C, Dunkler D, Marosi C , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
    CrossrefPubMedGoogle Scholar
  • 47 Moore RA, Adel N, Riedel E , et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
    CrossrefPubMedGoogle Scholar
  • 48 Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108 (6) 1042-1048
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (3) 291-292
    PubMedGoogle Scholar
  • 50 Mandalà M, Barni S, Prins M , et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21 (4) 871-876
    CrossrefPubMedGoogle Scholar
  • 51 Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 (Suppl. 01) S6-S9
    CrossrefPubMedGoogle Scholar
  • 52 Zwicker JI, Liebman HA, Bauer KA , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 2012; 160 (4) 530-537
    PubMedGoogle Scholar
  • 53 Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol 2010; 5 (6) 798-803
    CrossrefPubMedGoogle Scholar
  • 54 Sebastian AJ, Paddon AJ. Clinically unsuspected pulmonary embolism—an important secondary finding in oncology CT. Clin Radiol 2006; 61 (1) 81-85
    CrossrefPubMedGoogle Scholar
  • 55 Storto ML, Di Credico A, Guido F, Larici AR, Bonomo L. Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 2005; 184 (1) 264-267
    CrossrefPubMedGoogle Scholar
  • 56 Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Büller HR. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res 2010; 125 (6) e306-e309
    CrossrefPubMedGoogle Scholar
  • 57 Dentali F, Ageno W, Becattini C , et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010; 125 (6) 518-522
    CrossrefPubMedGoogle Scholar
  • 58 Carrier M, Righini M, Wells PS , et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8 (8) 1716-1722
    CrossrefPubMedGoogle Scholar
  • 59 Ageno W, Squizzato A, Togna A , et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost 2012; 10 (1) 158-160
    CrossrefPubMedGoogle Scholar
  • 60 Di Nisio M, Ferrante N, De Tursi M , et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (5) 1049-1054
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011; 106 (2) 371-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Font C, Farrús B, Vidal L , et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 2011; 22 (9) 2101-2106
    CrossrefPubMedGoogle Scholar
  • 63 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 (17) 2405-2409
    CrossrefPubMedGoogle Scholar
  • 64 O'Connell C, Razavi P, Ghalichi M , et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 2011; 9 (2) 305-311
    CrossrefPubMedGoogle Scholar
  • 65 Dentali F, Ageno W, Pierfranceschi MG , et al. Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (5) 1081-1083
    CrossrefPubMedGoogle Scholar
  • 66 Trujillo-Santos J, Prandoni P, Rivron-Guillot K , et al; RIETE Investigators. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008; 6 (2) 251-255
    CrossrefPubMedGoogle Scholar
  • 67 Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102 (6) V187-V194
    CrossrefPubMedGoogle Scholar
  • 68 Douketis JD, Gu C, Piccioli A, Ghirarduzzi A, Pengo V, Prandoni P. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009; 7 (4) 546-551
    CrossrefPubMedGoogle Scholar
  • 69 Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78 (5) 1316-1318
    PubMedGoogle Scholar
  • 70 Monreal M, Lafoz E, Casals A , et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1991; 67 (2) 541-545
    CrossrefPubMedGoogle Scholar
  • 71 Lee AY. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology (Am Soc Hematol Educ Program) 2006; 438-443
    PubMedGoogle Scholar
  • 72 Piccioli A, Lensing AW, Prins MH , et al; SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2 (6) 884-889
    CrossrefPubMedGoogle Scholar
  • 73 Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125 (10) 785-793
    CrossrefPubMedGoogle Scholar
  • 74 Hettiarachchi RJ, Lok J, Prins MH, Büller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998; 83 (1) 180-185
    CrossrefPubMedGoogle Scholar
  • 75 Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308 (6933) 891-894
    CrossrefPubMedGoogle Scholar
  • 76 Van Doormaal FF, Terpstra W, Van Der Griend R , et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted?. J Thromb Haemost 2011; 9 (1) 79-84
    CrossrefPubMedGoogle Scholar
  • 77 Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 1996; 239 (2) 153-156
    CrossrefPubMedGoogle Scholar
  • 78 Monreal M, Lensing AW, Prins MH , et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2 (6) 876-881
    CrossrefPubMedGoogle Scholar
  • 79 Sannella NA, O'Connor Jr DJ. “Idiopathic” deep venous thrombosis: the value of routine abdominal and pelvic computed tomographic scanning. Ann Vasc Surg 1991; 5 (3) 218-222
    CrossrefPubMedGoogle Scholar
  • 80 Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Intern Med 2008; 149 (5) 323-333
    CrossrefPubMedGoogle Scholar